Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up.
Anna ReltonAnna CollinsDavid S GutteryDiviya N GorsiaHilary J McDermottEsther L MossPublished in: European journal of cancer care (2021)
ctDNA monitoring to identify EC recurrence appears to be acceptable to patients, and for many, it may be preferable to clinical examination.